Press Releases Events & Presentations Event Details EASL 2023 – The International Liver Conference Jun 21 - Jun 24, 2023 Supporting Materials HBV/HDV entry inhibitor - A novel class of orally available small molecules potently inhibit hepatitis B and D virus entry 1.2 MB ABI-H3733 - Safety, pharmacokinetics, and antiviral activity of the next-generation hepatitis B core inhibitor ABI-H3733 in patients with hepatitis B e antigen negative chronic hepatitis B infection: preliminary results from a randomized, blinded, Phase 1 616.9 KB ABI-4334 - The safety and pharmacokinetics of ABI-4334, a novel next-generation HBV core inhibitor: interim results from a phase 1 study in healthy volunteers 471.6 KB ABI-H3733 and ABI-4334 - Next generation core inhibitors ABI-H3733 and ABI-4334 have significantly improved potency and target coverage for both antiviral and cccDNA formation activities compared to first-generation core inhibitors 1 MB Vebicorvir - Vebicorvir, entecavir, and pegylated interferon in patients with hepatitis B e antigen positive chronic hepatitis B virus infection: findings from a phase 2, randomized open-label study in China 551.8 KB Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
EASL 2023 – The International Liver Conference Jun 21 - Jun 24, 2023 Supporting Materials HBV/HDV entry inhibitor - A novel class of orally available small molecules potently inhibit hepatitis B and D virus entry 1.2 MB ABI-H3733 - Safety, pharmacokinetics, and antiviral activity of the next-generation hepatitis B core inhibitor ABI-H3733 in patients with hepatitis B e antigen negative chronic hepatitis B infection: preliminary results from a randomized, blinded, Phase 1 616.9 KB ABI-4334 - The safety and pharmacokinetics of ABI-4334, a novel next-generation HBV core inhibitor: interim results from a phase 1 study in healthy volunteers 471.6 KB ABI-H3733 and ABI-4334 - Next generation core inhibitors ABI-H3733 and ABI-4334 have significantly improved potency and target coverage for both antiviral and cccDNA formation activities compared to first-generation core inhibitors 1 MB Vebicorvir - Vebicorvir, entecavir, and pegylated interferon in patients with hepatitis B e antigen positive chronic hepatitis B virus infection: findings from a phase 2, randomized open-label study in China 551.8 KB
HBV/HDV entry inhibitor - A novel class of orally available small molecules potently inhibit hepatitis B and D virus entry 1.2 MB ABI-H3733 - Safety, pharmacokinetics, and antiviral activity of the next-generation hepatitis B core inhibitor ABI-H3733 in patients with hepatitis B e antigen negative chronic hepatitis B infection: preliminary results from a randomized, blinded, Phase 1 616.9 KB ABI-4334 - The safety and pharmacokinetics of ABI-4334, a novel next-generation HBV core inhibitor: interim results from a phase 1 study in healthy volunteers 471.6 KB ABI-H3733 and ABI-4334 - Next generation core inhibitors ABI-H3733 and ABI-4334 have significantly improved potency and target coverage for both antiviral and cccDNA formation activities compared to first-generation core inhibitors 1 MB Vebicorvir - Vebicorvir, entecavir, and pegylated interferon in patients with hepatitis B e antigen positive chronic hepatitis B virus infection: findings from a phase 2, randomized open-label study in China 551.8 KB
